Knoll Capital Management’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-160,000
Closed -$486K – 39
2026
Q2
$486K Hold
160,000
– – 0.23% 35
2026
Q1
$493K Sell
160,000
-961,524
-86% -$4.08M 0.27% 33
2025
Q4
$4.05M Hold
1,121,524
– – 1.86% 19
2025
Q3
$4.23M Hold
1,121,524
– – 2.27% 17
2025
Q2
$4.34M Hold
1,121,524
– – 3.09% 13
2025
Q1
$5.61M Hold
1,121,524
– – 3.65% 7
2024
Q4
$8.09M Hold
1,121,524
– – 5.21% 5
2024
Q3
$6.89M Hold
1,121,524
– – 3.19% 9
2024
Q2
$7.46M Buy
1,121,524
+554,305
+98% +$4.09M 5.03% 5
2024
Q1
$5.77M Buy
567,219
+367,219
+184% +$3.74M 3.59% 7
2023
Q4
$2.25M Buy
+200,000
New +$835K 1.86% 15
2023
Q3
– Sell
-173,864
Closed -$614K – 38
2023
Q2
$614K Hold
173,864
– – 0.74% 25
2023
Q1
$734K Hold
173,864
– – 1.13% 23
2022
Q4
$2.86M Hold
173,864
– – 6.45% 3
2022
Q3
$2.22M Buy
173,864
+40,886
+31% +$604K 1.3% 4
2022
Q2
$1.56M Hold
132,978
– – 0.89% 7
2022
Q1
$810K Hold
132,978
– – 0.51% 22
2021
Q4
$1.22M Hold
132,978
– – 0.67% 15
2021
Q3
$1.5M Buy
132,978
+82,978
+166% +$1.01M 0.75% 11
2021
Q2
$1.11M Hold
50,000
– – 0.58% 21
2021
Q1
$707K Hold
50,000
– – 0.46% 27
2020
Q4
$564K Buy
+50,000
New +$589K 0.38% 21

Other funds holding ALT

Knoll Capital Management's ALT Position: Q3 2026 in Review

Knoll Capital Management sold out of Altimmune (ALT) in Q3 2026, closing a stake of 160,000 shares — an estimated $486K sold.

Knoll Capital Management first reported a position in ALT in Q4 2020 and held it in 22 quarters. The position peaked at $8.09M in Q4 2024. 191 funds tracked by Wall St. Rank hold ALT as of Q3 2026.

  • Knoll Capital Management reported no remaining Altimmune position as of Q3 2026 after selling out during the quarter.
  • Knoll Capital Management sold 160,000 Altimmune shares in Q3 2026, an estimated $486K.
  • Knoll Capital Management first reported a position in Altimmune in Q4 2020 and held it in 22 quarters.
  • Knoll Capital Management's Altimmune position peaked at $8.09M in Q4 2024.
  • 191 funds tracked by Wall St. Rank held Altimmune as of Q3 2026.

Based on Knoll Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.